AC
FDMT icon

AXQ Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

AXQ Capital’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,755
Closed -$231K – 1083
2025
Q4 		$231K Buy
30,755
+17,876
+139% +$181K 0.05% 516
2025
Q3 		$112K Buy
+12,879
New +$77K 0.04% 512
2025
Q1 		– Sell
-19,753
Closed -$110K – 549
2024
Q4 		$110K Buy
+19,753
New +$155K 0.05% 375

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

AXQ Capital's FDMT Position: Q1 2026 in Review

AXQ Capital sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 30,755 shares — an estimated $231K sold.

AXQ Capital first reported a position in FDMT in Q4 2024 and held it in 3 quarters. The position peaked at $231K in Q4 2025. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • AXQ Capital reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AXQ Capital sold 30,755 4D Molecular Therapeutics shares in Q1 2026, an estimated $231K.
  • AXQ Capital first reported a position in 4D Molecular Therapeutics in Q4 2024 and held it in 3 quarters.
  • AXQ Capital's 4D Molecular Therapeutics position peaked at $231K in Q4 2025.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.